Drugs / yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01320683 | Mar 2011 → Dec 2014 | metastasis from malignant tumor of colon, rectal cancer | City of Hope Medical Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A | “Radiolabeled monoclonal antibodies, such as yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, can find tumor cells and carry tumor-killing substances to them without harming...” NCT01320683 ↗ |
| Modality | Monoclonal antibody | “Radiolabeled monoclonal antibodies, such as yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A” NCT01320683 ↗ |
| Route | Intravenous | “patients receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes” NCT01320683 ↗ |